Compare Affirm Holdings Inc (AFRM) vs IDEXX Laboratories, Inc. (IDXX) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Affirm Holdings Inc vs IDEXX Laboratories, Inc. — how do they compare? Affirm Holdings Inc trades at $76.83 (market cap $25.69B), while IDEXX Laboratories, Inc. trades at $588.36 (market cap $46.22B). The key difference: IDEXX Laboratories, Inc. is the larger of the two by market cap, and Affirm Holdings Inc is trading nearer its 52-week high, IDEXX Laboratories, Inc. nearer its low. Which is the better fit depends on your goals.
| AFRM | IDXX | |
|---|---|---|
Market Cap | $25.69B | $46.22B |
Sector | Financials | Health |
52-Week High | $92.18 | $766.68 |
52-Week Low | $42.53 | $526.44 |
Enterprise Value | $32.30B | $47.12B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Affirm Holdings (AFRM) trades at $73.42, down 2.81% on the day, amid a bullish technical outlook and strong fundamental momentum. The stock has consistently beaten earnings expectations in recent quarters, with revenue surging from $1.3B in 2022 to $3.22B in 2025, while achieving positive net income of $52.19M after years of losses. Analyst consensus is strongly bullish with a $95.75 price target, and institutional interest remains high.
AFRM presents a compelling growth story with accelerating profitability and expanding market share in fintech, though elevated valuation multiples and sensitivity to interest rate changes pose risks. The stock's upside potential hinges on sustained execution and macroeconomic stability, making it suitable for growth-oriented investors comfortable with volatility.
IDEXX Laboratories (IDXX) trades at $571.44, down 4.08% over the past day, amid a mixed technical and strong fundamental backdrop. The stock shows a bullish trend in moving averages but overbought RSI readings near 73. Recent Q2 2026 earnings beat expectations with 9% organic revenue growth, and the company raised full-year EPS guidance. Profitability remains robust with a 25.03% net income margin and 74.21% ROE.
The outlook is positive given strong earnings momentum, high analyst buy ratings, and a consensus price target of $683.33 implying ~20% upside. Risks include premium valuation multiples and potential market volatility. The stock presents a growth opportunity supported by durable competitive advantages in veterinary diagnostics.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Affirm Holdings Inc
Affirm Holdings Inc offers a platform for digital and mobile first commerce. It comprises a point-of-sale payment solution for consumers, merchant commerce solutions, and a consumer-focused app. The firm generates its revenue from merchant networks, and through virtual card networks among others. Geographically, it generates a major share of its revenue from the United States.
Read more on AFRM →About IDEXX Laboratories, Inc.
Idexx Laboratories primarily develops, manufactures, and distributes diagnostic products, equipment, and services for pets and livestock. Its key product lines include single-use canine and feline test kits that veterinarians can employ in the office, benchtop chemistry and hematology analyzers for test-panel analysis on-site, reference lab services, and tests to detect and manage disease in livestock. The firm also offers vet practice management software and consulting services to animal hospitals. Idexx gets about 38% of its revenue from outside the United States.
Read more on IDXX →
